June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Immune mediators in aqueous humor from patients with normal-tension glaucoma
Author Affiliations & Notes
  • Katsuhiko Maruyama
    ophthalmology, Tokyo Medical University, Shinjuku, Japan
  • Shunichiro Ueda
    ophthalmology, Tokyo Medical University, Shinjuku, Japan
  • Yoshihiko Usui
    ophthalmology, Tokyo Medical University, Shinjuku, Japan
  • Takeshi Kezuka
    ophthalmology, Tokyo Medical University, Shinjuku, Japan
  • Hiroshi Goto
    ophthalmology, Tokyo Medical University, Shinjuku, Japan
  • Footnotes
    Commercial Relationships Katsuhiko Maruyama, None; Shunichiro Ueda, None; Yoshihiko Usui, None; Takeshi Kezuka, None; Hiroshi Goto, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3486. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Katsuhiko Maruyama, Shunichiro Ueda, Yoshihiko Usui, Takeshi Kezuka, Hiroshi Goto; Immune mediators in aqueous humor from patients with normal-tension glaucoma. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3486.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Several studies have demonstrated that the levels of some immune mediators in aqueous humor are elevated in exfoliation glaucoma, pseudophakic glaucoma, primary open-angle glaucoma, and angle-closure glaucoma. However, the concentrations of immune mediators in normal-tension glaucoma (NTG) patients remain unclear. Therefore, we determined the immune mediator profile in aqueous humor samples obtained from medically treated eyes with NTG.

Methods: Twenty-six patients (26 eyes) with NTG undergoing trabeculectomy (NTG group) and 18 patients (18 eyes) with cataract undergoing phacoemulsification and intraocular lens implantation (control group) were enrolled in this cross-sectional study. Patients with a history of intraocular surgeries including laser treatment, or other ocular diseases were excluded. The ages in NTG group and control group were 52.4 +/- 6.4 (37-65) and 72.2 +/- 9.3 (51-90) years [mean +/- standard deviation (range)], respectively (p<0.001, independent t-test). Undiluted aqueous humor samples were collected at the start of surgery, and cytometric beads array kits were used to determine the concentrations of 28 immune mediators including angiogenin, interleukin (IL)-6, IL-8, vascular endothelium growth factor (VEGF), monokine induced by interferon gamma (Mig), interferon gamma inducible protein-10 (IP-10), and monocyte chemoattractant protein (MCP)-1. The levels of each immune mediator were compared between both groups using by multiple regression analysis. P <0.05 was considered significant.

Results: Angiogenin, IL-8, IP-10, Mig, and MCP-1 were detected in majority of cases. In NTG group and control group, the angiogenin levels were 5552.0 (1161.1-27316.4) and 5322.0 (3666.4-8245.0) pg/mL [median (range)], the IL-8 levels were 1.8 (0-20.0) and 2.0 (0-10.6) pg/mL, the IP-10 levels were 40.2 (0-269.4) and 66.9 (8.0-417.2) pg/mL, the Mig levels were 9.5 (0-104.0) and 29.8 (0-173.6) pg/mL, and the MCP-1 levels were 233.7 (136.8-806.3) and 340.1 (171.9-779.9) pg/mL, respectively. The differences were not statistically significant.

Conclusions: Our study suggests that there is no immune mediator to express specifically in medically treated NTG patients without history of intraocular surgery.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.